QuatRx gains $125M licensing pact

QuatRx has scored a $125 million licensing deal with Shionogi. The Japanese company will pay $25 million of that upfront for the worldwide marketing rights to ospemifene for the treatment of post-menopausal vulvovaginal atrophy. And NDA is planned later this year. QuatRx release